Anti-CCR5 antibody
View Patent ↗The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO14O-VK (ATCC Deposit Designation PTA-4097), and (ii) two heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVgl:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or a plasmic designated pVgl:HuPRO140 (mutB+D+I)-VH (ATCC Deposit Designation PTA-4099) or a fragment thereof which binds to CCR5 on the surface of a human cell.
1. A method of treating a subject afflicted with HIV-1 which comprises administering to the subject an effective HIV-1 treating dosage amount of (1) an anti-CCR5 antibody comprising (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO140-VK (ATCC Deposit Designation PTA-4097), and (ii) two heavy chains, each heavy chain comprising the expression product of either a plasmid designated pVg4:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or a plasmid designated pVg4:HuPRO140 (mut B+D+I)-VH (ATCC Deposit Designation PTA-4099), or a fragment of such antibody, which fragment binds to CCR5 on the surface of a human cell, and (2) one or more anti-viral agent, under conditions effective to treat said HIV-1-afflicted subject.
2. The method of claim 1 , wherein the anti-viral agent is selected from the group consisting of a nonnucleoside reverse transcriptase inhibitor, a nucleoside reverse transcriptase inhibitor, a HIV-1 protease inhibitor, and a HIV-1 fusion or viral entry inhibitor.
3. The method of claim 2 , wherein the nonnucleoside reverse transcriptase are selected from the group consisting of efavirenz, UC-781, HBY097, nevirapine, delavirdine, SJ-3366, MKC-442, GW420867x, and HI-443.
4. The method of claim 2 , wherein the nucleoside reverse transcriptase is selected from the group consisting of abacavir, lamivudine, zidovudine, stavudine, zacitabine, and didanosine.
5. The method of claim 2 , wherein the HIV-1 protease inhibitor is selected from the group consisting of lopinavir, saquinavir, nelfinavir mesylate, indinavir sulfate, amprenavir, and ritonavir.
6. The method of claim 2 , wherein the HIV-1 fusion or viral entry inhibitor is selected from the group consisting of a PRO542, a T-20, and a T-1249.
7. The method of claim 1 , wherein the anti-CCR5 antibody and the one or more anti-viral agent is administered to the subject by a method selected from the group consisting of intravenous, intramuscular and subcutaneous means.
8. The method of claim 1 , wherein the anti-CCR5 antibody is administered continuously to said subject.
9. The method of claim 1 , wherein the one or more anti-viral agent is administered continuously to said subject.
10. The method of claim 1 , wherein the anti-CCR5 antibody and the one or more antiviral agent are administered continuously to said subject.
11. The method of claim 1 , wherein the anti-CCR5 antibody is administered at predetermined periodic intervals to said subject.
12. The method of claim 1 , wherein the one or more anti-viral agent is administered at predetermined periodic intervals to said subject.
13. The method of claim 1 , wherein the anti-CCR5 antibody and the one or more anti-viral agent are administered at predetermined periodic intervals to said subject.
14. The method of claim 1 , wherein the dosage of the anti-CCR5 antibody ranges from about 0.1 to about 100,000 μg/kg body weight of said subject.
15. The method of claim 1 , wherein the dosage of the one or more anti-viral agent ranges from about 0.1 to about 100,000 μg/kg body weight of said subject.
16. The method of claim 14 , wherein the dosage of the anti-CCR5 antibody does not inhibit an endogenous chemokine activity on CCR5 in said subject.
17. The method of claim 1 , wherein the heavy chains comprise the expression product of the plasmid designated pVg4:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098).
18. The method of claim 1 , wherein the heavy chains comprise the expression product of the plasmid designated pVg4:HuPRO140 (mut B+D+I)-VH (ATCC Deposit Designation PTA-4099).
19. A method of preventing a subject from contracting an HIV-1 infection which comprises administering to the subject an effective HIV-1 infection-preventing dosage amount of (1) an anti-CCR5 antibody comprising (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO140-VK (ATCC Deposit Designation PTA-4097), and (ii) two heavy chains, each heavy chain comprising the expression product of either a plasmid designated pVg4:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or a plasmid designated pVg4:HuPRO140 (mut B+D+I)-VH (ATCC Deposit Designation PTA-4099), or a fragment of such antibody, which fragment binds to CCR5 on the surface of a human cell, and (2) one or more anti-viral agent, under conditions effective to treat said HIV-1-afflicted subject.
20. The method of claim 19 , wherein the anti-viral agent is selected from the group consisting of a nonnucleoside reverse transcriptase inhibitor, a nucleoside reverse transcriptase inhibitor, a HIV-1 protease inhibitor, and a HIV-1 fusion or viral entry inhibitor.
21. The method of claim 20 , wherein the nonnucleoside reverse transcriptase are selected from the group consisting of efavirenz, UC-781, HBY097, nevirapine, delavirdine, SJ-3366, MKC-442, GW420867x, and HI-443.
22. The method of claim 20 , wherein the nucleoside reverse transcriptase is selected from the group consisting of abacavir, lamivudine, zidovudine, stavudine, zacitabine, and didanosine.
23. The method of claim 20 , wherein the HIV-1 protease inhibitor is selected from the group consisting of lopinavir, saquinavir, nelfinavir mesylate, indinavir sulfate, amprenavir, and ritonavir.
24. The method of claim 20 , wherein the HIV-1 fusion or viral entry inhibitor is selected from the group consisting of a PRO542, a T-20, and a T-1249.
25. The method of claim 19 , wherein the anti-CCR5 antibody and the one or more anti-viral agent is administered to the subject by a method selected from the group consisting of intravenous, intramuscular and subcutaneous means.
26. The method of claim 19 , wherein the anti-CCR5 antibody is administered continuously to said subject.
27. The method of claim 19 , wherein the one or more anti-viral agent is administered continuously to said subject.
28. The method of claim 19 , wherein the anti-CCR5 antibody and the one or more antiviral agent are administered continuously to said subject.
29. The method of claim 19 , wherein the anti-CCR5 antibody is administered at predetermined periodic intervals to said subject.
30. The method of claim 19 , wherein the one or more anti-viral agent is administered at predetermined periodic intervals to said subject.
31. The method of claim 19 , wherein the anti-CCR5 antibody and the one or more anti-viral agent are administered at predetermined periodic intervals to said subject.
32. The method of claim 19 , wherein the dosage of the anti-CCR5 antibody ranges from about 0.1 to about 100,000 μg/kg body weight of said subject.
33. The method of claim 19 , wherein the dosage of the one or more anti-viral agent ranges from about 0.1 to about 100,000 μg/kg body weight of said subject.
34. The method of claim 32 , wherein the dosage of the anti-CCR5 antibody does not inhibit an endogenous chemokine activity on CCR5 in said subject.
35. The method of claim 19 , wherein the heavy chains comprise the expression product of the plasmid designated pVg4:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098).
36. The method of claim 19 , wherein the heavy chains comprise the expression product of the plasmid designated pVg4:HuPRO140 (mut B+D+I)-VH (ATCC Deposit Designation PTA-4099).